BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $214,119 | -15.1% | 4,670 | -5.1% | 0.02% | -24.2% |
| Q4 2022 | $252,279 | -99.9% | 4,921 | -16.6% | 0.03% | -25.0% |
| Q3 2022 | $319,000,000 | -16.3% | 5,898 | 0.0% | 0.04% | -10.2% |
| Q2 2022 | $381,000,000 | -15.1% | 5,898 | +2.2% | 0.05% | 0.0% |
| Q1 2022 | $449,000,000 | -7.6% | 5,773 | +2.3% | 0.05% | -2.0% |
| Q4 2021 | $486,000,000 | +6.6% | 5,644 | 0.0% | 0.05% | -5.7% |
| Q3 2021 | $456,000,000 | 0.0% | 5,644 | 0.0% | 0.05% | -1.9% |
| Q2 2021 | $456,000,000 | -4.4% | 5,644 | 0.0% | 0.05% | -11.5% |
| Q1 2021 | $477,000,000 | +104966.1% | 5,644 | 0.0% | 0.06% | -1.6% |
| Q4 2020 | $454,000 | -0.2% | 5,644 | 0.0% | 0.06% | -10.1% |
| Q3 2020 | $455,000 | -9.5% | 5,644 | -3.1% | 0.07% | -14.8% |
| Q2 2020 | $503,000 | +6.1% | 5,826 | 0.0% | 0.08% | -12.0% |
| Q1 2020 | $474,000 | -99.9% | 5,826 | +12.6% | 0.09% | +16.5% |
| Q4 2019 | $434,000,000 | +95494.7% | 5,173 | 0.0% | 0.08% | -12.2% |
| Q3 2019 | $454,000 | +6.8% | 5,173 | 0.0% | 0.09% | +4.7% |
| Q2 2019 | $425,000 | +1.0% | 5,173 | 0.0% | 0.09% | -3.4% |
| Q1 2019 | $421,000 | +26.8% | 5,173 | +3.0% | 0.09% | -9.2% |
| Q4 2018 | $332,000 | – | 5,023 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |